Cited by 15,256

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Open access

Wanchoo, Rimda, Karam, Sabine, Uppal, Nupur N., Barta, Valerie S., Deray, Gilbert, Devoe, Craig, Launay-Vacher, Vincent, Jhaveri, Kenar D., on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors·2017·American Journal of Nephrology

DOI 10.1159/000455014

Open this paper in CoChat — free account

Abstract

Background: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. Summary: In order to provide an extensive overview of the renal toxicities induced by these agents, a Medline search was conducted of published literature related to ipilimumab-, pembrolizumab-, and nivolumab-induced kidney toxicity. In addition, primary data from the initial clinical trials of these agents and the FDA adverse reporting system database were also reviewed to determine renal adverse events. Acute interstitial nephritis (AIN), podocytopathy, and hyponatremia were toxicities caused by ipilimumab. The main adverse effect associated with both the PD-1 inhibitors was AIN. The onset of kidney injury seen with PD-1 inhibitors is usually late (3-10 months) compared to CTLA-4 antagonists related renal injury, which happens earlier (2-3 months). PD-1 as opposed to CTLA-4 inhibitors has been associated with kidney rejection in transplantation. Steroids appear to be effective in treating the immune-related adverse effects noted with these agents. Key Message: Although initially thought to be rare, the incidence rates of renal toxicities might be higher (9.9-29%) as identified by recent studies. As a result, obtaining knowledge about renal toxicities of immune checkpoint inhibitors is extremely important.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1159/000455014

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415

Show all 14 references

Research works printed but not linked: 35

10.1016/j.coi.2015.11.001 · DOI
10.1016/S0065-2776(06)90001-7 · DOI · Paper page
10.1177/1060028015586218 · DOI
10.18632/oncotarget.2980 · DOI
10.1007/s11912-012-0284-2 · DOI
10.1016/j.kint.2016.04.008 · DOI · Paper page
10.1371/journal.pone.0053745 · DOI · Paper page
10.1097/MJT.0b013e3182a32ddc · DOI
10.1093/annonc/mdq013 · DOI · Paper page
10.1056/NEJMc0904283 · DOI · Paper page
10.1200/JCO.2011.41.4359 · DOI
10.1007/s10637-014-0092-7 · DOI
10.1016/j.kint.2015.11.028 · DOI
10.1007/s12032-010-9794-7 · DOI
10.1016/j.clineuro.2014.06.011 · DOI
10.1158/1078-0432.CCR-14-2607 · DOI · Paper page
10.1016/S0140-6736(14)60958-2 · DOI · Paper page
10.1016/S1470-2045(15)00083-2 · DOI · Paper page
10.1158/2326-6066.CIR-13-0146 · DOI
10.1053/j.ajkd.2016.02.057 · DOI · Paper page
10.1016/j.ctrv.2016.02.003 · DOI · Paper page
10.1200/JCO.2014.58.3708 · DOI · Paper page
10.1200/JCO.2013.53.0105 · DOI · Paper page
10.1016/S1470-2045(15)70076-8 · DOI · Paper page
10.1093/ckj/sfw024 · DOI
10.1007/s11523-016-0426-9 · DOI
10.4049/jimmunol.1400497 · DOI
10.4049/jimmunol.179.11.7466 · DOI
10.1093/ndt/gfl818 · DOI
10.1681/ASN.2006050418 · DOI · Paper page
10.1200/JCO.2013.49.2314 · DOI
10.1056/NEJMc1509268 · DOI · Paper page
10.1111/ajt.13711 · DOI
10.1093/annonc/mdw130 · DOI
10.1111/ajt.13786 · DOI

Items 201–300 of 647

STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620
First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Pilon-Thomas, S., Kodumudi, K. N., El-Kenawi, A. E., Russell, S., Weber, A. M., Luddy, K., Damaghi, M., Wojtkowiak, J. W., Mulé, J. J., Ibrahim-Hashim, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1743 · Cited by 593
Digital pathology and artificial intelligence in translational medicine and clinical practice
Baxi, V., Edwards, R., Montalto, M., & Saha, S. (2022) · Modern Pathology · doi:10.1038/s41379-021-00919-2 · Cited by 592
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells
Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
Huang, J., Liu, D., Wang, Y., Liu, L., Li, J., Yuan, J., Jiang, Z., Jiang, Z., Hsiao, W. W., Liu, H., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-321031 · Cited by 539
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
The immunological synapse
Dustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer
Ganesan, A.-P., Clarke, J., Wood, O., Garrido-Martin, E. M., Chee, S. J., Mellows, T., Samaniego-Castruita, D., Singh, D., Seumois, G., Alzetani, A., et al. (2017) · Nature Immunology · doi:10.1038/ni.3775 · Cited by 528
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Capone, M., Giannarelli, D., Mallardo, D., Madonna, G., Festino, L., Grimaldi, A. M., Vanella, V., Simeone, E., Paone, M., Palmieri, G., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0383-1 · Cited by 497
Genetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
Aptamer-based targeted therapy
Zhu, G., & Chen, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.005 · Cited by 522
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511
Cardiovascular toxicities associated with immune checkpoint inhibitors
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox208 · Cited by 486
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459
COX2/mPGES1/PGE 2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612920114 · Cited by 494
Cancer immunotherapies: advances and bottlenecks
Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
PD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer
Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466
Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
Lee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01695-5 · Cited by 464
Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study
Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00975 · Cited by 463
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S. A., Lin, K., Quaglino, P., Rappersberger, K., & Ortiz-Urda, S. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1916 · Cited by 449
Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456
T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01830-8 · Cited by 449
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Nutrition, inflammation and cancer
Zitvogel, L., Pietrocola, F., & Kroemer, G. (2017) · Nature Immunology · doi:10.1038/ni.3754 · Cited by 446
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Schadendorf, D., Wolchok, J. D., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Chesney, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2289 · Cited by 441
Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging
Thomas, R., Wang, W., & Su, D.-M. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-0173-8 · Cited by 442
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01406-6 · Cited by 437
B lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
Axelrad, J. E., Lichtiger, S., & Yajnik, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i20.4794 · Cited by 431
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00050-2017 · Cited by 412
PD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
Belum, V. R., Benhuri, B., Postow, M. A., Hellmann, M. D., Lesokhin, A. M., Segal, N. H., Motzer, R. J., Wu, S., Busam, K. J., Wolchok, J. D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.010 · Cited by 418
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Das, R., Bar, N., Ferreira, M., Newman, A. M., Zhang, L., Bailur, J. K., Bacchiocchi, A., Kluger, H., Wei, W., Halaban, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96798 · Cited by 423
NFATc1 Regulates PD-1 Expression upon T Cell Activation
Oestreich, K. J., Yoon, H., Ahmed, R., & Boss, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4832 · Cited by 416
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101305 · Cited by 381
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413
Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial
Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01998 · Cited by 408
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383
Innate immune signaling and regulation in cancer immunotherapy
Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., Abudayyeh, A., Mamlouk, O., Motwani, S. S., Murakami, N., Herrmann, S. M., Manohar, S., Shirali, A. C., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070676 · Cited by 407
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
Vanguri, R. S., Luo, J., Aukerman, A. T., Egger, J. V., Fong, C. J., Horvat, N., Pagano, A., Araujo-Filho, J. D. A. B., Geneslaw, L., Rizvi, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00416-8 · Cited by 395
Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
Ricciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Pollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., Ancell, K. K., Long, G. V., Menzies, A. M., Eroglu, Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx642 · Cited by 393
Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Paczulla, A. M., Rothfelder, K., Raffel, S., Konantz, M., Steinbacher, J., Wang, H., Tandler, C., Mbarga, M., Schaefer, T., Falcone, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1410-1 · Cited by 391
Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
The role of gut microbiota in cancer treatment: friend or foe?
Cheng, W. Y., Wu, C.-Y., & Yu, J. (2020) · Gut · doi:10.1136/gutjnl-2020-321153 · Cited by 384
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Padrón, L. J., Maurer, D. M., O’Hara, M. H., O’Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01829-9 · Cited by 384
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Goswami, S., Walle, T., Cornish, A. E., Basu, S., Anandhan, S., Fernandez, I., Vence, L., Blando, J., Zhao, H., Yadav, S. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0694-x · Cited by 356
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821218116 · Cited by 359
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
Song, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T. J., Li, J., Dorosheva, O., Liu, T., Liu, R., & Huang, L. (2018) · Nature Communications · doi:10.1038/s41467-018-04605-x · Cited by 375
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
Liu, Y., Zhou, N., Zhou, L., Wang, J., Zhou, Y., Zhang, T., Fang, Y., Deng, J., Gao, Y., Liang, X., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00850-9 · Cited by 372
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1116 · Cited by 367
Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
Liu, J., Li, S., Zhang, S., Liu, Y., Ma, L., Zhu, J., Xin, Y., Wang, Y., Yang, C., & Cheng, Y. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22964 · Cited by 364

Authors: Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
Venue: American Journal of Nephrology
Publisher: S. Karger AG
Published: 2017
Volume: 45
Issue: 2
Pages: 160-169
ISSN: 0250-8095 (ISSN-L)
1421-9670
DOI: 10.1159/000455014
OpenAlex: W2572174216
Cited by: 15,256
References: 14
FWCI: 180.98
Type: journal article
Language: en
Open access: bronze
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources